2027 ICD-10-CM Diagnosis Code E16.3Increased secretion of glucagon
ICD-10-CM Codes›E00–E89›E15-E16›E16
- Billable — Valid for Submission
- Chronic Condition
E16.3 is a billable ICD-10-CM diagnosis code for increased secretion of glucagon. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 643 through 645. Coders also document this condition as abnormality of secretion of glucagon. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified endocrine disorders.
E16.3 does not risk-adjust for Medicare Advantage under the CMS-HCC V28 model. It still risk-adjusts in the RxHCC Part D (V08) category 66 for payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
E16.3 does not risk-adjust for Medicare Advantage under the CMS-HCC V28 model, but it maps to payment categories in the other CMS models shown below.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Abnormality of secretion of glucagon
- Excessive glucagon secretion
- GCGR-related hyperglucagonemia
- Glucagon resistance
- Hyperplasia of islet alpha cells with glucagon excess
- Islet cell hyperplasia
- Non-diabetic disorder of endocrine pancreas
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to E16.3: its own notes plus those printed at Chapter 4. A note printed at a category, block or chapter applies to every code under it.
Applicable To
Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.
- Hyperplasia of pancreatic endocrine cells with glucagon excess
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Notes
General instructions on how these codes are used.
- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name E16.3, its category, or a range that includes it.
Excludes1 1
These codes carry an Excludes1 note naming E16.3: they are not reported together with it, unless the two conditions are unrelated.
- E74 Other disorders of carbohydrate metabolismincreased secretion of glucagon (E16.3)
Code First 1
These codes say to code first a condition named in the note, and E16.3 is one of the conditions named.
- G63 Polyneuropathy in diseases classified elsewhere
Notes 1
These notes mention E16.3.
- Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseasesAll neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere. names E16-E31, which includes this code
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Abnormal, abnormality, abnormalities See Also: Anomaly;
glucagon secretion E16.3
glucagon E16.3
glucagon E16.3
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Patient EducationClinical
Pancreatic Diseases
The pancreas is a gland behind your stomach and in front of your spine. It produces juices that help break down food and hormones that help control blood sugar levels. Problems with the pancreas can lead to many health problems. These include:
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E16.3 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About E16.3Overview
What is the ICD-10 code for increased secretion of glucagon?
The ICD-10-CM code for increased secretion of glucagon is E16.3 (sometimes written as E163). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is E16.3 (Other disorders of pancreatic internal secretion) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report increased secretion of glucagon on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does E16.3 group to?
When increased secretion of glucagon is the principal diagnosis on an inpatient stay, it groups to MS-DRG 644, 645, 643, with relative weights from 0.7461 to 1.6138 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of E16.3?
Under the General Equivalence Mappings, increased secretion of glucagon converts to ICD-9-CM 251.4 (abn secretion glucagon). The mapping is a direct match.
Does E16.3 risk-adjust for Medicare Advantage payment?
Not for Medicare Advantage: E16.3 maps to no category in the CMS-HCC V28 model. It still risk-adjusts in the RxHCC Part D (V08) category 66 (Pancreatic Disorders and Intestinal Malabsorption, Except Pancreatitis).
